Brief: Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

Cartesian Therapeutics

13/11/2025 21:11

Nov 13 (Reuters) - Cartesian Therapeutics Inc RNAC.O:

CARTESIAN THERAPEUTICS ANNOUNCES STRONG EFFICACY SIGNAL IN PHASE 2 TRIAL OF DESCARTES-08 IN PATIENTS WITH SLE AND EXPANSION OF CLINICAL DEVELOPMENT INTO MYOSITIS

CARTESIAN - 100% LLDAS RESPONSE RATE OBSERVED IN PATIENTS WITH SLE WHO GOT DESCARTES-08 IN PHASE 2 OPEN-LABEL TRIAL REACHING MONTH 3 FOLLOW-UP

CARTESIAN THERAPEUTICS INC - CARTESIAN PLANS TO PAUSE FURTHER DEVELOPMENT OF DESCARTES-08 IN SLE

CARTESIAN THERAPEUTICS INC - PLANS TO PAUSE DEVELOPMENT OF DESCARTES-15 TO PRIORITIZE OPPORTUNITIES FOR DESCARTES-08 IN MG AND MYOSITIS

CARTESIAN: MYOSITIS SEAMLESS ADAPTIVE CLINICAL TRIAL DESIGN PROVIDES POTENTIAL OPPORTUNITY FOR SINGLE PIVOTAL TRIAL EXPECTED TO COMMENCE IN 1H26

Source text: ID:nGNXbGZZSb

Further company coverage: RNAC.O

 ((Reuters.Briefs@thomsonreuters.com;))